IFNG and neoplasm: In addition, gene expression signatures like immune-predictive score (IMPRES) and IFN-γ-responsive genes expressed in tumors or tumor immune microenvironments (TiME) have also been implicated in predicting response of metastatic melanoma to ICB therapies7,8,11–20.